Below are the most recent publications written about "Antineoplastic Agents, Immunological" by people in Profiles.
-
Zarrabi KK, Vaishampayan U, Barata PC. Enhancing the Immunogenicity of Nivolumab plus Ipilimumab with Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2024 Dec; 10(6):879-881.
-
Park SJ, Ellison DM, Weight R, Homsi J, Rabinowits G, Ruiz ES, Strasswimmer J, Simmons J, Panella T, Quek RG, Pouliot JF, Khushalani NI. CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma. Future Oncol. 2025 Feb; 21(4):431-436.
-
Necchi A, Roumigui? M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024 Jun; 25(6):720-730.
-
Vlachou E, Mamtani R, Hahn NM, Iii BJ, Hoffman-Censits J, Nimgaonkar V. Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin. Clin Genitourin Cancer. 2024 Jun; 22(3):102090.
-
Grajales V, Martini A, Shore ND. Complications of immuno-oncology care: what urologist should know. BJU Int. 2024 05; 133(5):524-531.
-
Harel M, Lahav C, Jacob E, Dahan N, Sela I, Elon Y, Raveh Shoval S, Yahalom G, Kamer I, Zer A, Sharon O, Carbone DP, Dicker AP, Bar J, Shaked Y. Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. J Immunother Cancer. 2022 Jun; 10(6).
-
Cohen F, Yuan H, Silberstein SD. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale. BioDrugs. 2022 May; 36(3):341-358.
-
Ghosh A, Harish Bindiganavile S, Bhat N, Lee AG. A Case of Miller Fisher Syndrome Due to the Use of Cemiplimab. J Neuroophthalmol. 2021 Sep 01; 41(3):e343-e345.
-
Karadag AS, Wang JV, Parish LC. Monoclonal Antibodies: Magic Bullets Since 1975. Skinmed. 2021; 19(4):249-251.
-
Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Kolb EA, Aplenc R, Meshinchi S, Raimondi SC, Hirsch B, Gamis AS. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2021 10 01; 39(28):3149-3160.